This morning the Federal Circuit released two nonprecedential opinions and one nonprecedential order. Both nonprecedential opinions come in patent cases appealing decisions of the Patent Trail and Appeal Board. The nonprecedential order is a dismissal. Here are the introductions to the opinions and a link to the dismissal.
Qualcomm Inc. v. Intel Corp. (Nonprecedential)
Qualcomm Incorporated (“Qualcomm”) appeals the final written decisions issued in four inter partes review (“IPR”) proceedings in which the Patent Trial and Appeal Board (“Board”) found claims 1-15, 17-25, and 27-33 of U.S. Patent No. 9,608,675 (“’675 patent”) unpatentable as obvious. Intel Corporation (“Intel”) cross-appeals the final written decisions in two other IPR proceedings in which the Board found claims 1-3, 5, 7-15, 17-21, 23-25, and 27- 30 of the same ’675 patent not obvious. We affirm in Qualcomm’s appeal and dismiss Intel’s cross-appeal.
Novartis Pharma AG v. Regeneron Pharmaceticals, Inc. (Nonprecedential)
Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation (collectively, Novartis) appeal from a Patent Trial and Appeal Board (Board) final written decision finding all claims of U.S. Patent No. 9,220,631 (’631 patent) unpatentable under 35 U.S.C. § 103. See Regeneron Pharms., Inc. v. Novartis Pharma AG, No. IPR2021-00816, 2022 WL 18460885, at *48 (P.T.A.B. Oct. 25, 2022) (Decision). Novartis raises a laundry list of fact-intensive arguments. For the following reasons, we affirm.